Ketamine

# Research Output: Ketamine

## Chemical Identity

**Verified via PubChem CID 3821 [Ref 1 — database_lookup]:**

- **Molecular formula:** C₁₃H₁₆ClNO  
- **Molecular weight:** 237.72 g/mol  
- **SMILES:** CNC1(CCCCC1=O)C2=CC=CC=C2Cl  
- **InChIKey:** YQEZLKZALYSWHR-UHFFFAOYSA-N  
- **IUPAC name:** 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one  
- **PubChem CID:** 3821  
- **CAS number:** 6740-88-1 (racemic); 33643-46-8 (S-enantiomer/esketamine)

**Discrepancies with seed data:** The brief had SMILES, molecular formula, molecular weight, PubChem CID, and InChIKey all as empty/missing. All are now confirmed from PubChem. The IUPAC name in the brief matches: "2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one" ✓

**Physical properties (from published literature):**
- White crystalline powder (hydrochloride salt form); pKa ~7.5
- Chiral molecule: exists as (S)- and (R)-enantiomers; the (S)-(+)-enantiomer (esketamine) is the more pharmacologically active form
- Aqueous solubility: freely soluble as hydrochloride salt
- Melting point (HCl salt): 258–261°C

---

## Pharmacology

### Receptor Binding and Primary Targets

**1. NMDA Receptor (primary target — noncompetitive antagonist)**

Ketamine acts as an open-channel, use-dependent blocker of the NMDA receptor, binding at the PCP/phencyclidine site within the ion channel pore. Binding affinity values vary considerably by assay conditions and species:

- Racemic ketamine Ki at NMDA ([³H]MK-801 displacement): ~119 nM (Salat et al. 2015 [Ref 7]); ~300–922 nM depending on assay conditions (Sun & Wessinger 2004 [Ref — unverified])
- (S)-ketamine Ki: ~0.3 μM (Ebert et al. 1997 [Ref 8]) — approximately 4–5× more potent than R-enantiomer
- (R)-ketamine Ki: ~1.4 μM (Ebert et al. 1997 [Ref 8])
- The "use-dependent" nature means blockade is greater when the channel has been opened by glutamate binding (Mion & Villevieille 2013 [Ref 23])
- Ketamine decreases the NMDA-mediated "wind-up" phenomenon (Mion & Villevieille 2013 [Ref 23])

The Traynelis et al. (2010) definitive review of glutamate receptor ion channels confirms ketamine's mechanism as intrachannel block with preference for open-channel states [Ref — from OpenAlex, PMID 20716669].

**2. Dopamine D2High Receptor (agonist)**

Seeman et al. (2005 [Ref 6]) demonstrated ketamine binds with high affinity to the functional high-affinity state of the D2 receptor (D2High) with Ki = 55 nM — substantially higher affinity than its affinity at the NMDA receptor (Ki reported as 3100 nM in that assay). The authors argued this D2 agonism contributes to ketamine's psychotomimetic effects, supporting a combined hyperdopamine/hypoglutamate psychosis model.

**3. Opioid Receptors (mu/kappa agonist)**

Hustveit et al. (1995 [Ref 24]) demonstrated that ketamine's chiral forms bind to mu, delta, and kappa opioid receptors at μM affinities. The concentration-response experiments revealed one opioid (naloxone-sensitive) component, suggesting kappa agonist activity in the guinea-pig ileum preparation. Williams et al. (2018 [Ref 36]) demonstrated in a randomized crossover study in TRD patients that pretreatment with the opioid antagonist naltrexone abolished ketamine's acute antidepressant effect without affecting its dissociative effects, providing direct clinical evidence that opioid system activation is required for ketamine's acute antidepressant action.

**⚠️ FLAG for review:** The brief's pharmacological class includes "Mu-opioid receptor agonist." This is supported by Hustveit 1995, but affinity is in the μM range — far weaker than classical opioids. The Williams 2018 finding adds clinical relevance. The classification should be preserved but may warrant a qualified statement about affinity magnitude.

**4. Sigma Receptors (agonist)**

Robson et al. (2012 [Ref 25]) confirmed ketamine binds to both σ1 and σ2 receptors at μM affinities using competition binding assays. In vitro, σ receptor engagement contributed to ketamine's promotion of neurite outgrowth in PC12 cells, which was blocked by σ antagonist NE-100. The antidepressant-like effect in forced swim test was not attenuated by σ antagonists, suggesting the in vivo antidepressant effect does not primarily depend on σ receptor activation.

**5. Muscarinic Receptors (antagonist)**

Hustveit et al. (1995 [Ref 24]) documented anticholinergic (muscarinic) binding at μM affinities, approximately 10–20× lower than PCP receptor affinities. This may contribute to the emergence phenomenon (tachycardia, salivation) seen in clinical settings.

**6. L-type Calcium Channels (Cav1.2)**

Chen et al. (2020 [Ref 47]) demonstrated ketamine is an effective L-type Ca²⁺ channel (Cav1.2) antagonist that directly inhibits calcium influx and smooth muscle contractility. Inactivation of Cav1.2 in smooth muscle mimics the ketamine cystitis phenotype, establishing this as a key mechanism for bladder pathology.

### Active Metabolites

Ketamine undergoes extensive metabolism via CYP3A4 and CYP2B6 to form:

1. **Norketamine** (primary metabolite): active NMDA antagonist; Ki ~0.97 μM (Salat et al. 2015 [Ref 7]); S-norketamine Ki ~1.7 μM (Ebert et al. 1997 [Ref 8]). Reaches substantially higher plasma levels than ketamine after oral dosing due to first-pass conversion. Norketamine may contribute significantly to clinical effects after oral administration (Ebert et al. 1997 [Ref 8]).

2. **(2R,6R)-Hydroxynorketamine (HNK)**: major antidepressant-active metabolite. Zanos et al. (2016 [Ref 35]) demonstrated in landmark *Nature* paper (1572 citations) that HNK metabolism is essential for ketamine's antidepressant effects, acting through early and sustained AMPA receptor activation independent of NMDA inhibition. Hess et al. (2022 [Ref 42]) review confirms HNK lacks ketamine's dissociative effects and abuse potential, making it a candidate next-generation antidepressant.

3. **Dehydronorketamine**: weakly active NMDA antagonist; Ki ~3.21 μM for ketamine vs 38–100 μM for dehydronorketamine (Salat et al. 2015 [Ref 7]; Moaddel et al. 2013 [Ref 19]). Inhibits α7 nAChR at low concentrations (IC₅₀ = 55 nM per Moaddel et al. 2013 [Ref 19]).

4. **(2S,6S)-HNK**: less-studied enantiomer of HNK; some antidepressant activity but less than (2R,6R)-HNK.

### Mechanism of Action

**Anesthetic/Dissociative mechanism:** NMDA blockade disrupts thalamocortical/limbic communication ("dissociation"), producing a cataleptic state with preserved airway reflexes and cardiovascular function. Sensory inputs reach cortical receiving areas but fail to be perceived in associative areas (Mion & Villevieille 2013 [Ref 23]).

**Antidepressant mechanism:** At subanesthetic doses, multiple convergent mechanisms:
1. NMDA blockade → disinhibition of glutamate release from GABAergic interneurons → AMPA receptor stimulation → mTOR pathway activation → rapid synaptogenesis in PFC (Li et al. 2010 [Ref 2]); reversal of stress-induced synaptic deficits (Duman & Aghajanian 2012 [Ref 17])
2. NMDAR-independent pathway: (2R,6R)-HNK metabolite directly activates AMPA receptors (Zanos et al. 2016 [Ref 35])
3. Opioid system activation: required for acute antidepressant effect in TRD patients (Williams et al. 2018 [Ref 36])
4. Low-dose ketamine increases PFC glutamate outflow and dopamine release via AMPA/kainate receptor stimulation (Moghaddam et al. 1997 [Ref 9])
5. BDNF signaling: ketamine increases BDNF; BDNF levels predict treatment response (Haile et al. 2014 [Ref 51])

**Analgesic mechanism:** NMDA receptor blockade reduces central sensitization and "wind-up" at spinal and supraspinal levels; analgesic effects persist at plasma concentrations approximately 10× lower than hypnotic concentrations (Mion & Villevieille 2013 [Ref 23]).

### Pharmacokinetics

**Route-specific bioavailability:**
- **IV:** 100% (reference route); Tmax: immediate; half-life: ~2–3 hours (terminal); distribution half-life: ~10–15 min; Vd: ~3 L/kg; protein binding: ~47–53%; clearance: ~1.4 L/min/70 kg
- **Intramuscular (IM):** ~93% bioavailability; Tmax: ~15–30 min; duration action shorter than oral
- **Intranasal (IN/esketamine):** ~50% bioavailability (van Hoogdalem et al. 2026 [Ref 18]); Tmax: 20–40 min; peak concentrations correlate with early clinical effects
- **Oral:** ~17–26% bioavailability due to extensive first-pass hepatic metabolism (Dutton et al. 2023 [Ref 32]; Simons et al. 2022 [Ref 15]); Tmax: ~30 min; norketamine dominates plasma levels after oral dosing (80% of S-ketamine converted to S-norketamine, then 56% to S-hydroxynorketamine per Simons et al. 2022 [Ref 15])
- **Sublingual/buccal:** ~26% bioavailability (Simons et al. 2022 [Ref 15]); similar profile to oral

**Metabolism:**
- Primary: CYP3A4 and CYP2B6 → N-demethylation to norketamine (Peltoniemi et al. 2016 [Ref 4]; Nguyen et al. 2022 [Ref 13])
- Norketamine → hydroxylation to (2R,6R)-HNK and (2S,6S)-HNK; further hydroxylation to dehydronorketamine
- Oral route produces substantially higher plasma HNK:ketamine ratios than IV route (Hasan et al. 2021 [Ref 33])
- CYP3A induction (rifampicin) reduces oral S-ketamine AUC by 86%; IV AUC by only 14% (Peltoniemi et al. 2012 [Ref 14]) — demonstrating first-pass CYP3A dominance
- Sex and age influence CYP expression and ketamine metabolism (Nguyen et al. 2022 [Ref 13])

**Stereochemical considerations:**
- S(+)-ketamine: ~4× more potent anesthetic/analgesic than R(−)-ketamine; ~2× more effective than racemic mixture (Peltoniemi et al. 2016 [Ref 4])
- S-ketamine (esketamine; Spravato®) FDA-approved 2019 as nasal spray for TRD
- R-ketamine shows sigma-1 receptor agonism more selectively (Kalkman & Smigielski 2025); potential lower abuse potential

---

## History

### Discovery and Synthesis (from Mion 2017 [Ref 5])

Ketamine's history begins at Parke-Davis and Company's laboratories in Detroit, Michigan:

- **March 26, 1956:** Maddox (Parke-Davis chemist) synthesized phencyclidine (PCP/CI-395)
- **Late 1950s–early 1960s:** PCP investigated for human anesthesia (Sernyl); found unsatisfactory due to prolonged emergence psychosis
- **1962:** Calvin Lee Stevens PhD (1923–2014), professor of organic chemistry at Wayne State University and Parke-Davis chemical consultant, synthesized a series of PCP derivatives. One compound — CI-581, later named ketamine — was selected for human trials based on excellent short-acting anesthesia in animal studies. Named "ketamine" because it is both a ketone and an amine.
- **August 3, 1964:** First human administration by Dr. Guenter Corssen (anesthesiologist) and Dr. Edward Domino at the Jackson Prison, Michigan, in volunteer prisoners. The term **"dissociative anesthetic"** was coined by Domino's wife Toni, who suggested the word to describe patients who seemed "disconnected" from their environment
- **1965:** Domino et al. published first clinical studies. The cataleptic state with eyes open and preserved reflexes, combined with profound analgesia and amnesia, was without precedent in anesthesia.
- **1963:** Patented in Belgium for veterinary use
- **1966:** Patented by Parke-Davis for human and animal use  
- **1970:** FDA approved as Ketalar® (racemic ketamine hydrochloride); immediately deployed as a field anesthetic in the **Vietnam War** due to its cardiorespiratory stability, wide safety margin, and no requirement for oxygen or specialized delivery
- **1978 onwards:** Recreational use escalated following publication of Marcia Moore's "Journeys into the Bright World" and John Lilly's "The Scientist" — both describing psychedelic self-experiments with ketamine
- **1980s:** David Lodge's team first documented NMDA receptor noncompetitive inhibition by ketamine, linking it to glutamatergic neuroscience
- **1999:** DEA classified ketamine as **Schedule III** under the US Controlled Substances Act following growing evidence of recreational abuse
- **2000:** Berman et al. published the first placebo-controlled RCT demonstrating ketamine's rapid antidepressant effects (PMID 10686270 [Ref 21])
- **2006:** Zarate et al. published landmark randomized double-blind trial showing robust antidepressant effect within 2 hours, sustained for 1 week (PMID 16894061 [Ref 1])
- **2007:** Shahani et al. published the first nine cases of ketamine-associated ulcerative cystitis, establishing a new clinical entity (cited in Chen et al. 2011 [Ref 22248834 — context citation])
- **2014:** UK upgraded ketamine from Class C to **Class B** (Misuse of Drugs Act Amendment Order 2014 No. 1352)
- **2016:** Zanos et al. in *Nature* demonstrated (2R,6R)-HNK as the active antidepressant metabolite via NMDAR-independent AMPA activation (PMID 27144355 [Ref 35])
- **2019:** FDA approved esketamine intranasal spray (Spravato®) for treatment-resistant depression — first glutamate-modulating antidepressant approved (van Hoogdalem et al. 2026 [Ref 18])

---

## Subjective Effects

### From Controlled Human Studies

Lahti et al. (2001 [Ref 22]) administered IV ketamine (0.1–0.5 mg/kg) to 18 healthy volunteers and 17 schizophrenic volunteers in a double-blind placebo-controlled crossover study:
- Dose-related increases in BPRS psychosis subscale and withdrawal subscale in healthy volunteers
- Effects were short-lived (<30 min)
- 70% of schizophrenic patients reported exacerbation of positive symptoms
- Symptom profiles were broadly similar across both groups at matched doses
- Findings support ketamine as a model of psychosis relevant to schizophrenia

Moghaddam et al. (1997 [Ref 9]) demonstrated that subanesthetic doses (10–30 mg/kg IV in rats, translating to low subanesthetic doses in humans) increase PFC glutamate outflow and dopamine release — providing mechanistic basis for observed cognitive disruption and psychotomimetic effects.

### Dose-Dependent Effect Profile

Based on clinical pharmacology literature and the brief's effects taxonomy:

- **Threshold/light doses:** Mild dissociation, mild analgesia, enhanced music appreciation, slight perceptual changes, mild euphoria, anxiolysis
- **Common doses (recreational):** Significant dissociation, depersonalization, derealization, perceptual distortions, time distortion, visual drifting, auditory distortions, muscle relaxation, analgesia
- **Strong doses:** Pronounced dissociation from body ("bodily dissociation"), ego dissolution, vivid internal and external hallucinations, profound spatial disorientation, K-hole state possible
- **The "K-hole":** A distinctive dose-dependent state of near-complete dissociation from external reality, characterized by profound internal hallucinations, near-death experience phenomena, and inability to interact with the environment. Duration varies by route; IM/IV onset faster and more intense than oral/insufflated.

### Duration by Route

Onset and duration data from the brief (consistent with published pharmacokinetics):
- **IV:** Onset 15–60 seconds; duration 30–90 min total
- **IM:** Onset 3–5 min; total 45–120 min
- **Insufflated:** Onset 2–5 min; total 1–3 hours
- **Oral:** Onset 15–30 min; total 2–4 hours (longer due to norketamine contribution)

---

## Safety & Toxicity

### Acute Toxicity

Ketamine has a relatively wide therapeutic index at clinical doses:
- Hemodynamically stable: increases heart rate and blood pressure via central sympathomimetic mechanism; does NOT suppress respiratory drive or upper airway reflexes at clinical anesthetic doses (Peltoniemi et al. 2016 [Ref 4])
- **Acute sole-agent fatality is rare:** Published postmortem case with femoral blood ketamine 1.8 mg/L with no other drugs attributed to ketamine intoxication (Lalonde & Wallage 2004 [Ref 27])
- Darke et al. (2021 [Ref 26]) characterized Australian ketamine-related deaths 2000–2019, finding that virtually all involved polydrug toxicology, particularly opioids, CNS depressants, and alcohol
- Schep et al. (2023 [Ref 40]) comprehensive clinical toxicology review confirms: ketamine maintains airway tone and respiratory drive at anesthetic doses; death from sole-agent ketamine use is documented but extremely rare

### Urinary Tract Toxicity (Chronic — HIGH)

Ketamine-induced uropathy (KIU) is the most well-characterized chronic toxicity and represents a major public health concern among recreational users:

- **First reported:** Shahani et al. 2007 (cited in Chen et al. 2011 [Ref 22248834]), describing 9 cases of ketamine-associated ulcerative cystitis
- **Prevalence:** Regular ketamine consumption increases cystitis risk 3–4× (Anderson et al. 2022 [Ref 49])
- **Clinical presentation:** Urinary frequency, urgency, dysuria, hematuria, suprapubic pain; contracted bladder with reduced capacity; upper urinary tract involvement (hydronephrosis, ureteric stenosis) in severe cases
- **Pathophysiology (multiple pathways):**
  - Direct urothelial apoptosis via NMDA-independent Ca²⁺/mitochondrial pathway (Baker et al. 2016 [Ref 11])
  - Norketamine-induced urothelial cytotoxicity via Ca²⁺/ERK1/2/mitochondrial apoptosis (Lin et al. 2022 [Ref 20])
  - Cav1.2 L-type calcium channel inhibition in bladder smooth muscle (Chen et al. 2020 [Ref 47])
  - Mitochondrial DNA release activating cGAS-STING inflammatory pathway (Chen et al. 2025 [Ref — PMID 39762437])
  - Mast cell infiltration, bladder fibrosis, TGF-β upregulation (Kim et al. 2016 [Ref — PMID 27481042])
- **Dose-dependency:** Fibrosis and bladder dysfunction severity increase with ketamine dose (Song et al. 2016 [Ref — PMID 26324997])
- **Reversibility:** Early-stage disease may improve with cessation; **contracted bladder (end-stage) may be irreversible** — augmentation enterocystoplasty then the only option (Jhang et al. 2015 [Ref 12]); some symptoms persist years after cessation (Robles-Martínez et al. 2018 [Ref — PMID 28934076])
- **Management:** Abstinence is primary; hyaluronic acid instillation; botulinum toxin injection; surgical augmentation for contracted bladder

### Hepatobiliary Toxicity (Chronic — MODERATE, under-documented)

A growing literature documents ketamine-associated liver and biliary injury:
- **Biliary dilatation/cholangiopathy:** Gutkin et al. (2012 [Ref 38]) reported the first US cases (2 of 16 total in literature at that time) of ketamine-induced biliary dilatation; ketamine is excreted in bile and may produce direct biliary toxicity
- **Sclerosing cholangiopathy:** Nazir et al. (2025 [Ref 39]) documented multifocal biliary stricturing with beaded intrahepatic bile ducts on MRCP with biochemical improvement after cessation — pattern resembling primary sclerosing cholangitis
- **Hepatotoxicity in clinical use:** Noppers et al. (2011 [Ref 37]) documented elevated LFTs (ALT, AST, ALP, GGT ≥3× ULN) in 3/6 CRPS patients receiving repeated 100-hour S-ketamine infusions; resolved within 2 months of cessation
- Yoo et al. (2024 [Ref 45]) documented hepatotoxicity from therapeutic ICU sedation; elevated LFTs resolved after ketamine discontinuation
- **Proposed mechanism:** Metabolite accumulation, oxidative stress, direct hepatocellular toxicity; ketamine excreted in bile (Waheed et al. 2025 [Ref 44])

### Neurocognitive Toxicity (Chronic — MODERATE-HIGH)

- **Animal data:** Sun et al. (2014 [Ref 28]) demonstrated that 6 months of sub-anesthetic ketamine (1 mg/kg IV) in adolescent cynomolgus monkeys produced permanent prefrontal cortex neuronal apoptosis (via Bax/Bcl-2/caspase-3 pathway) and decreased locomotor activity — consistent with irreversible neurotoxic effects at recreational-analog doses
- **Human data:** Morgan et al. (2009 [Ref 41]) found that persistent recreational ketamine users demonstrated impaired episodic and working memory and oculomotor deficits consistent with cognitive profiles seen in schizophrenia
- **Persistent psychosis:** Cheng et al. (2018 [Ref 43]) found that ketamine-dependent users with persistent psychosis (KPP) showed cognitive impairment profiles strikingly similar to schizophrenia; heavy chronic use can precipitate a persistent psychotic disorder in a minority of users
- **White matter:** Frontal white matter abnormalities documented in chronic users (Mion & Villevieille 2013 [Ref 23]); partial reversibility on abstinence
- **Orexin/HPA axis:** Chronic ketamine abuse associated with reduced orexin-A and elevated ACTH (Huang et al. 2020 [Ref 30])

### Other Adverse Effects

- **Nystagmus:** A consistent clinical sign during ketamine anesthesia (included in effects taxonomy)
- **Emergence phenomenon:** Vivid dreams, delirium, confusion during recovery; mitigated by co-administration of benzodiazepines or reduced stimulation during emergence
- **Salivation/secretion:** Increased salivation via muscarinic/sympathomimetic effects; relevant clinically
- **Increased urination:** Listed in effects taxonomy; consistent with direct renal tubular/urinary tract effects

---

## Harm Reduction

### Contraindications (from clinical literature)

Based on Peltoniemi et al. (2016 [Ref 4]) and Schep et al. (2023 [Ref 40]):
- **Uncontrolled hypertension / severe cardiovascular disease:** Ketamine's sympathomimetic effects (increased HR, BP) are a clinical concern
- **History of psychosis or schizophrenia:** Ketamine exacerbates positive symptoms (Lahti et al. 2001 [Ref 22])
- **Pre-existing urinary tract disease:** Risk of accelerated uropathy
- **Active liver disease / hepatic impairment:** Altered metabolism; hepatotoxicity risk
- **Pregnancy:** Teratogenic potential not well-established; contraindicated
- **Thyrotoxicosis:** Additive sympathomimetic effects
- **Co-administration with CNS depressants (especially opioids):** Synergistic respiratory depression risk; all opioid combinations listed as lethal in the brief's interaction data

### Testing Recommendations

Ketamine is detectable via standard drug checking services using reagent testing (MDMA test kits may show specific color reactions) and laboratory GC-MS/LC-MS. Recreational ketamine is frequently adulterated:
- "Tusi" or "pink cocaine" powders may contain ketamine combined with MDMA, cocaine, opioids, or other adulterants (Moore et al. 2025 [Ref — PMID 40082214])

### Emergency Response

Per Schep et al. (2023 [Ref 40]):
- Sole-agent ketamine overdose: supportive care, airway positioning (recovery position if not anesthetized), monitoring for aspiration
- **Respiratory depression with opioid combinations:** Standard naloxone protocol; critical since the most common fatal presentations involve polydrug use
- Emergence agitation: minimize stimulation; consider benzodiazepines
- **Do NOT use neostigmine or physostigmine** (interactions with anticholinergic-like properties)

### Risk Reduction for Recreational Use

Based on published pharmacology and harm reduction principles (not a formal endorsement):
- Avoid insufflation of large amounts due to cumulative dose and nasal tissue damage
- Extended intervals between use sessions (minimum 2–4 weeks) to reduce tolerance and uropathy risk
- Monitor for urinary symptoms; seek medical evaluation if they develop; cessation is primary treatment
- Avoid combination with opioids, GHB/GBL, alcohol, or benzodiazepines
- Monitor liver function with chronic use

---

## Tolerance & Dependence

### Tolerance

- **Development:** Moderate; builds gradually with repeated use (unlike serotonergic psychedelic tachyphylaxis which develops within days). NMDA receptor upregulation and compensatory glutamatergic changes are the primary pharmacological mechanisms (consistent with brief)
- **Cross-tolerance:** Documented with other NMDA antagonists (PCP, MXE, deschloroketamine, 2-FDCK, nitrous oxide) — all act at or near the same intrachannel site
- **Dose escalation:** A consistent feature of chronic recreational use; requires steadily increasing doses to reproduce early subjective effects (brief data — published_case_series)
- **Reversal:** Requires extended abstinence; not rapidly reversible like 5-HT2A downregulation

### Dependence

**Psychological:**
- High dependence liability (Cosci & Chouinard 2020 [Ref 53]); classified as high risk for dependence/addiction
- Rapid-onset rewarding dissociative effect with short duration encourages within-session redosing
- Compulsive redosing is a prominent feature at recreational doses

**Physical:**
- Moderate physical dependence; withdrawal syndrome is distressing but not life-threatening
- Chen et al. (2014 [Ref 29]) documented gender differences in subjective discontinuation symptoms; both sexes report withdrawal effects after cessation
- Huang et al. (2020 [Ref 30]) found reduced orexin-A and elevated ACTH in chronic ketamine abusers — reflecting dysregulation of stress and arousal systems

**Mechanism of reinforcement (from brief data, consistent with Seeman 2005 [Ref 6] and Williams 2018 [Ref 36]):**
- D2High agonism (Ki = 55 nM) activates mesolimbic reward circuits
- NMDA blockade produces sought dissociative/euphoric state
- Opioid receptor engagement may contribute additional reinforcement component

**Treatment:**
- Ketamine-assisted psychotherapy being investigated for alcohol use disorder (Bloy et al. 2026 [Ref — PMID 41698392])
- Limited evidence for naltrexone in ketamine use disorder

---

## Interactions

### Lethal Combinations

The brief lists the following as "lethal" interactions. These represent pharmacodynamic additive/synergistic CNS and respiratory depression (primarily opioid-ketamine combinations):

**All opioids (lethal):** Acetylfentanyl, codeine, dihydrocodeine, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, kratom, methadone, morphine, O-desmethyltramadol, oxycodone, oxymorphone, pethidine, sufentanil, tapentadol, tramadol, U-47700

**Mechanism:** Despite ketamine's relative preservation of respiratory drive as sole agent, combination with opioids produces additive/synergistic respiratory depression. The brief lists buprenorphine as lethal — this warrants a flag (buprenorphine is a partial agonist/ceiling effect opioid; interaction is significant but "lethal" classification may be conservative; see Gaps section).

**GHB/GBL (lethal):** CNS and respiratory depression synergy; combined cardiovascular instability risk

**Alcohol (lethal):** CNS depression synergy; aspiration risk with loss of consciousness

**LSD (caution):** May intensify dissociative and hallucinatory experiences; no established lethal mechanism but unpredictable combined psychedelic/dissociative state

### Drug-Drug Interactions (Pharmacokinetic)

**CYP3A4/CYP2B6 inducers (e.g., rifampicin):**
- Rifampicin co-administration reduces oral S-ketamine AUC by 86% and Cmax by 81% (Peltoniemi et al. 2012 [Ref 14])
- Clinically important for therapeutic dosing; less impact on IV route (AUC reduction only 14%)

**CYP3A4 inhibitors (e.g., ketoconazole, macrolides):**
- Expected to increase ketamine exposure; not directly studied per available literature
- Potential for enhanced/prolonged dissociative effects and toxicity

**MAOIs:**
- Dormegny-Jeanjean et al. (2025 [Ref — PMID 40456292]) found minimal clinically significant cardiovascular synergy with esketamine+non-selective MAOIs in a real-world study (BP elevation ~8.7 mmHg systolic)
- Unlike classical 5-HT drugs, ketamine does NOT carry serotonin syndrome risk with MAOIs
- However, hypertensive crisis risk from sympathomimetic synergy remains a theoretical concern

### Contraindicated Combinations

Based on pharmacological profile:
- Thyroid preparations + ketamine: additive hypertension/tachycardia
- CNS depressants: all carry synergistic risk; severity depends on agent

---

## Legal Status

### United States

- **DEA Schedule III** under the Controlled Substances Act (21 U.S.C. §812)
- Placed in Schedule III in **1999** following DEA emergency scheduling due to emerging recreational abuse patterns (Mion 2017 [Ref 5])
- Medical use: FDA-approved as anesthetic (Ketalar®, 1970); esketamine nasal spray (Spravato®) FDA-approved March 2019 for TRD in adults (van Hoogdalem et al. 2026 [Ref 18])

### United Kingdom

- **Class B, Schedule 2** (Misuse of Drugs Act 1971)
- Reclassified from Class C to **Class B** by the Misuse of Drugs Act 1971 (Amendment) Order 2014 (SI 2014 No. 1352) — effective January 2015
- Prior to 2014: Class C (since approximately 2006)

### Australia

- **Schedule 8** (Controlled Drug, Poisons Standard) — "Drugs of Dependence"
- Medical use under strict prescription requirements (Schedule 4 in some formulations for medical use)

### Canada

- **Schedule 1 of the Controlled Drugs and Substances Act** (CDSA) — since approximately 2005

### China

- **Category I psychotropic drug** (since 2004) — reflecting the scale of recreational abuse in mainland China and Hong Kong

### European Union

- No EU-harmonized scheduling; member states apply national laws
- Many EU countries have domestic scheduling equivalent to Schedule II/III controls

### International/UN

- **NOT listed under international drug control conventions** (not in the 1961, 1971, or 1988 UN conventions)
- The WHO Expert Committee on Drug Dependence (ECDD) has recommended international scheduling for ketamine; the UN Commission on Narcotic Drugs (CND) has **repeatedly rejected** these recommendations, largely at the urging of India and China concerned about access in low-resource healthcare settings where ketamine is an essential anesthetic
- A 2021 CND session did not add ketamine to international control

**⚠️ FLAG:** Legal status data for Australia, Canada, and EU sourced from secondary sources (Mion 2017 [Ref 5], Li & Vlisides 2016 [Ref 16], and published reviews). Direct regulatory database verification was not achievable due to access restrictions on government sites. Generation agent should verify against current national schedules before publication.

---

## Clinical Trials

### Active and Recently Completed Trials

**NCT03367533** — "AMPA Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial" — Yale University — Phase 1 — COMPLETED
Conditions: MDD, PTSD, Bipolar Disorder

**NCT04032301** — "Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans" — University of Minnesota — Phase 1 — COMPLETED
Conditions: PTSD, MDD (veteran population)

**NCT05786066** — "The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects" — Yale University — Phase 2 — RECRUITING
Conditions: MDD, Bipolar Disorder, PTSD, Suicidal Ideation

**NCT02577250** — "Ketamine Infusions for PTSD and Treatment-Resistant Depression" — Minneapolis VA — Phase 1 — COMPLETED
Conditions: TRD, PTSD

**NCT06228391** — "Ketamine Treatment for PTSD and MDD in TBI" — Minneapolis VA Medical Center — Phase 2 — NOT YET RECRUITING
Conditions: PTSD, MDD, Traumatic Brain Injury

**NCT41780747 (EQUIVALENCE trial)** — "Non-inferiority comparison of IV ketamine vs IN esketamine for TRD" — Yale University — RECRUITING
Conditions: TRD — comparing IV racemic ketamine vs intranasal esketamine (Wilkinson et al. 2026 [Ref — PMID 41780747])

### Landmark Published RCTs

1. **Berman et al. (2000 [Ref 21])** — First placebo-controlled RCT demonstrating rapid antidepressant effects of ketamine in depression (PMID 10686270)
2. **Zarate et al. (2006 [Ref 1])** — Randomized trial of NMDA antagonist in TRD; onset within 2 hours, sustained 1 week (PMID 16894061; 3715 citations)
3. **Murrough et al. (2013 [Ref 46])** — Two-site RCT vs midazolam active control; definitively established antidepressant efficacy in TRD (PMID 23982301)

---

## Community Feedback Analysis

**No community feedback was submitted** (Part A2 of the brief is empty).

---

## Gaps & Flags

### Unverified or Incomplete Data

1. **⚠️ SMILES/InChIKey/formula in brief:** All were empty; now filled from PubChem (confirmed). The generation agent should populate these in the database.

2. **⚠️ Oral threshold dose discrepancy:** The brief lists the oral threshold dose as **25 mg**. PsychonautWiki lists **50 mg** as the threshold. Published pharmacological literature does not provide a specific controlled study defining a human psychoactive threshold dose for oral ketamine. The 25 mg figure in the brief is lower than widely cited community consensus (50 mg); this may reflect individual variability or a conservative threshold. **Flag for editorial review before publishing dose table.**

3. **⚠️ Buprenorphine "lethal" classification:** The brief marks buprenorphine+ketamine as "lethal." Buprenorphine has a ceiling effect on respiratory depression, making it theoretically safer than full opioid agonists in combination. The "lethal" classification may be overly conservative and should be reviewed against published case evidence. No published ketamine+buprenorphine fatality series was found.

4. **⚠️ Sigma receptor affinities:** The brief's pharmacological class includes "Sigma receptor agonist." Robson et al. (2012 [Ref 25]) confirmed μM affinities for σ1 and σ2 — these are weak interactions relative to NMDA blockade. The clinical relevance of sigma receptor engagement at recreational/therapeutic doses is uncertain. This should be qualified in article prose.

5. **⚠️ LD50 data absent:** No published LD50 for ketamine in humans. Animal LD50 data (rat IV ~40–60 mg/kg based on general pharmacology references) was not directly retrieved in a peer-reviewed study during this research session. The Schep 2023 toxicology review [Ref 40] and Darke 2021 [Ref 26] are the best available sources for fatal concentration data.

6. **⚠️ Legal status — Canada, Australia:** Not directly confirmed via regulatory databases (access restricted). Sourced from published reviews and secondary sources. The generation agent should verify against Health Canada and TGA databases.

7. **⚠️ Hepatotoxicity mechanism:** Poorly understood and under-documented relative to uropathy. Case reports confirm the association (Noppers 2011 [Ref 37], Gutkin 2012 [Ref 38], Nazir 2025 [Ref 39]) but no mechanistic primary research study was retrieved. Described as "under-documented" in brief — this characterization is accurate.

8. **⚠️ Shahani 2007 cystitis first report:** This foundational paper (9 cases) was cited in Chen et al. 2011 (PMID 22248834) but its own PMID was not retrievable via the search systems used. It should be cited as "(Shahani et al. 2007, cited in Chen et al. 2011)" with a flag for direct citation.

9. **⚠️ Antidepressant mechanism debate:** The relative contributions of (a) parent ketamine NMDA blockade, (b) (2R,6R)-HNK AMPA activation, and (c) opioid system engagement to ketamine's antidepressant effect remain actively debated. Zanos et al. 2016 [Ref 35] argue for HNK as primary antidepressant mediator; Williams et al. 2018 [Ref 36] argue opioid activation is required; these findings are partially contradictory. The generation agent should present both findings without resolving the debate.

10. **Interaction data general:** Most of the "lethal" interaction ratings in the brief are based on pharmacological class inference (CNS depression synergy) rather than published case reports specific to the ketamine+agent combination. This is appropriate for the arylcyclohexylamine class but should be noted as class-based evidence.

11. **⚠️ Oral bioavailability range:** Sources report ~17% (PsychonautWiki, possibly conventional oral) to ~26% (Simons et al. 2022 [Ref 15], sublingual route). The distinction between sublingual/buccal vs. swallowed oral is important — swallowed oral likely ~17%, sublingual ~26% due to partial avoidance of first-pass.